{"contentid": 488475, "importid": NaN, "name": "FDA accepts Takeda\u00e2\u0080\u0099s mobocertinib for priority review", "introduction": "The US Food and Drug Administration has granted priority review for the company\u00e2\u0080\u0099s New Drug Application (NDA) for mobocertinib (TAK-788), Japan\u00e2\u0080\u0099s largest drugmaker Takeda Pharmaceutical announced today.", "content": "<p>The US Food and Drug Administration has granted priority review for the company&rsquo;s New Drug Application (NDA) for mobocertinib (TAK-788), Japan&rsquo;s largest drugmaker Takeda Pharmaceutical (TYO: 4502) announced today.</p>\n<p>The drug candidate is intended for the treatment of adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC), as detected by an FDA-approved test, who have received prior platinum-based chemotherapy. Mobocertinib is the first oral therapy specifically designed to selectively target EGFR Exon20 insertion mutations.</p>\n<p>The FDA has set a Prescription Drug User Fee Act (PDUFA) target actions date for mobocertinib of October 26, 2021.</p>\n<p>USA-based oncology firm Spectrum Pharmaceuticals (Nasdaq: SPPI) is also testing an oral EGF tyrosine kinase inhibitor (EGFR TKI), poziotinib, in the ZENITH20 trial, as an option for people with pre-treated non-small cell lung cancer (NSCLC) with exon 20 insertions.</p>\n<h2><strong>Current options provide limited benefit</strong></h2>\n<p>&ldquo;Patients with EGFR Exon20 insertion+ mNSCLC face considerable challenges, as current treatment options provide limited benefit, resulting in poor survival outcomes,&rdquo; said Christopher Arendt, head, Oncology Therapeutic Area Unit, Takeda adding: &ldquo;We are excited to be one step closer to offering mobocertinib as an effective oral therapy for NSCLC patients with EGFR Exon20 insertions that have received prior platinum-based chemotherapy and look forward to continuing conversations with regulatory agencies in the US and around the globe.&rdquo;</p>\n<p>The NDA for mobocertinib is primarily based on results from the <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takedaoncology.com%2Fmedia%2Fnews-media%2Fnews-releases%2FTakeda-Presents-Positive-Results-For-Mobocertinib-in-Patient-11751%2F&amp;esheet=52419303&amp;newsitemid=20210427006162&amp;lan=en-US&amp;anchor=Phase+1%2F2+trial&amp;index=2&amp;md5=85c246400da415a064badfa418d2b38e\">Phase I/II trial</a>, which is evaluating the safety and efficacy of oral mobocertinib in patients with mNSCLC. The application was submitted under the FDA&rsquo;s accelerated approval program<strong><em>. </em></strong>The review is being conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE), which provides a framework for concurrent submission and review of oncology products among international partners.</p>\n<p>Takeda has established an Expanded Access Program (EAP) for patients in the US who may be eligible to receive access to mobocertinib during the review of the NDA.</p>\n<h2><strong>About mobocertinib </strong></h2>\n<p>Mobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) Exon20 insertion mutations. In 2019, the US FDA granted mobocertinib Orphan Drug designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations.</p>\n<p>In April 2020, mobocertinib received Breakthrough Therapy designation from the FDA for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after platinum-based chemotherapy.</p>\n<p>In October 2020, mobocertinib was designated as a Breakthrough Therapy in China by the Center for Drug Evaluation (CDE) for locally advanced or metastatic NSCLC patients with EGFR Exon20 insertion mutations who have been previously treated with at least one prior systemic chemotherapy.</p>", "date": "2021-04-28 10:16:00", "meta_title": "FDA accepts Takeda\u00e2\u0080\u0099s mobocertinib for priority review", "meta_keywords": "Takeda, Mobocertinib, TAK-788, Priority review, Cancer, Lung, mNSCLC, EGFR Exon20", "meta_description": "FDA accepts Takeda\u00e2\u0080\u0099s mobocertinib for priority review", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-28 10:06:45", "updated": "2021-04-28 10:16:41", "access": NaN, "url": "https://www.thepharmaletter.com/article/fda-accepts-takeda-s-mobocertinib-for-priority-review", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "takeda_corporate_large.jpg", "image2id": "takeda_corporate_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Asia Pacific, Focus On, Regulation, US FDA", "geography_tag": "Japan, USA", "company_tag": "Takeda", "drug_tag": "mobocertinib, TAK-788", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-28 10:16:00"}